To whom it may concern:

Company Name: TOHO HOLDINGS CO.,LTD.

Corporate Hiromi Edahiro, Representative Director,

Representative: President and CEO

(Prime Market of Tokyo Stock Exchange

Securities Code: 8129)

Contact: Makoto Kawamura, Executive Corporate Officer

and General Manager, Corporate Strategy

Division

(TEL: 81-3-6838-2803)

Notice Regarding the Establishment of New Logistics Centers in the Tokai and Tohoku Regions

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, President and CEO: Hiromi Edahiro) announces that it will establish TBC Tokai in Komaki City, Aichi as a high-performance logistics center for prescription pharmaceuticals and other products in the Tokai region. It also announces the establishment of a new logistics hub in the Tohoku region.

1. Background and objectives of establishing the new logistics centers

To fulfill its social mission of providing a stable supply of pharmaceuticals, the Group aims to contribute to the maintenance of healthcare delivery systems through high-quality logistics established through tireless creativity and ingenuity, and to continue to be a company that is needed by society.

In order to continuously respond to the diversification of drug discovery modalities and the increasing demand for pharmaceuticals in recent years, and to further strengthen our logistics network, we have decided to establish the TBC Tokai logistics center. By making it work with existing TBC DynaBASE and TBC Hanshin to reorganize the supply area and supply volume, we will solidify our rapid and stable pharmaceutical supply system across the three major metropolitan areas of Tokyo, Nagoya, and Osaka. At the same time, by optimizing the logistics network, including sales offices, we will significantly reduce inventories at sales offices and the burden of delivery and other operations. We will also create an environment where sales personnel can focus more on providing information at medical sites through further promoting the separation of commercial transactions and physical distribution. We believe that the opening of this center will achieve drastic reform in sales and logistics and lead directly to the establishment of a competitive advantage in our pharmaceutical wholesaling business.

We are also considering establishing a new logistics hub in the Tohoku region. By placing logistics centers in major metropolitan areas nationwide, we will build a more robust pharmaceutical supply system.

2. TBC Tokai

(1) Outline of TBC Tokai

a. Location: 391-1, Takinakamachi, Komaki City, Aichi

b. Total floor space: 25,875 m²

c. Capital investment amount: Total JPY 5 billion (approximate)

d. Date of Completion: February 2027

e. Start of Operation: Within FY2027

f. Number of product lines: 25,000 items

g. Product lines: Prescription pharmaceuticals, reagents, medical equipment, regenerative medical products,

medical supplies etc.

h. Coverage area: Aichi, Shizuoka, Gifu, Shiga, Mie and Nagano Prefectures

(2) Characteristics of TBC Tokai

a. Next-generation logistics center that combines thorough labor saving and high-spec processing capacity

Integrating years of expertise in automation technology, we will introduce a flexible, expandable and

redundant XY shuttle system into automated warehouses. By building a flexible system with autonomous

mobile robots that greatly reduces conveyor equipment, we will dramatically improve shipping processing

capacity and productivity. In addition, high shipping accuracy and complete, customer-specific packaging

reduce ancillary tasks for delivery personnel and realize the optimization of delivery.

b. Integrated logistics center featuring both manufacturer warehouse and wholesale warehouse

In addition to significantly reducing transportation costs and time by eliminating the transportation process

between manufacturers and wholesalers, and optimizing inventory throughout the supply chain, we will

realize an efficient, secure, and safe supply that eliminates quality risks when transporting specialty

pharmaceuticals such as regenerative medical products.

c. Business Continuity Plan

Taking advantage of its location adjacent to a Main Wide-Area Disaster Management Base Facility currently

under construction, we aim to contribute to the pharmaceutical supply system in the event of a disaster with

a view to cooperating with local governments and the Japan Self-Defense Forces.

Furthermore, by linking systems among logistics centers nationwide, we will construct a highly redundant

distribution network in which backup functions are activated immediately in the event of a system failure.

d. Initiatives for Sustainability Management

We will promote energy conservation in the entire facility by introducing self-consumption photovoltaic

power generation, EVs and EV charging stations, and centralized control of air conditioning and lighting

using a comprehensive monitoring panel equipped with energy management systems (EMS) and energy-

saving control functions. Additionally, the use of regenerative converters in automated warehouses and

battery-powered transport equipment such as autonomous mobile robots will significantly reduce power

consumption during operation.

2



[Completed Image]

3. Establishment of a new logistics hub in Tohoku

To accommodate future growth in the handling volume of pharmaceuticals and other products and to increase productivity through the qualitative improvement and strengthening of our sales and logistics systems currently underway, we will establish a new logistics center in Tohoku.

Outline of new logistics hub in the Tohoku region

a. Location: Sendai City, Miyagi

b. Key Features: Drug storage and distribution centers

c. Start of Construction: Scheduled for 2026

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.